Related references
Note: Only part of the references are listed.Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Andrew N. Phillips et al.
LANCET HIV (2020)
Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort
Nicolo Girometti et al.
HIV MEDICINE (2020)
Sexually Transmitted Infections and Human Immunodeficiency Virus
Robin M. Lawson
NURSING CLINICS OF NORTH AMERICA (2020)
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Willem D F Venter et al.
Lancet HIV (2020)
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Alexandra Calmy et al.
Lancet HIV (2020)
Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir
Mariana Veloso Meireles et al.
AIDS (2019)
A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients
Ryosaku Ota et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2019)
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1
A. Ayouba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
Mario Cruciani et al.
PLOS ONE (2019)
Benefits and risks of rapid initiation of antiretroviral therapy
Nathan Ford et al.
AIDS (2018)
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis
Steve Kanters et al.
LANCET HIV (2017)
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
George W. Rutherford et al.
PLOS ONE (2016)
Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV
Christopher E. Kandel et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection
R. Chris Rathbun et al.
ANNALS OF PHARMACOTHERAPY (2014)
Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up
Frederick J. Lee et al.
PLOS ONE (2014)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen et al.
LANCET INFECTIOUS DISEASES (2012)
Share Paper
